학술논문
SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated with Gemcitabine, S-1, or Gemcitabine plus S-1
Document Type
Article
Author
Source
In: Pancreas . (Pancreas, 1 May 2018, 47(5):637-642)
Subject
Language
English
ISSN
15364828
08853177
08853177